AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23230999
Drug: Doxylamine hydrogen
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxylamine hydrogen succinate 25 mg under fasting conditions
Trial: 10568115
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (Duraflo II, n = 20)
Trial: 8911631
Drug: IVIG infusions
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG infusions (200-250 mg/kg) every 3 weeks during the first 8 months of pregnancy
Trial: 1868270
Drug: Synthetic hPTH
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle, followed by no other therapy (Group 1)
Trial: 1868270
Drug: Synthetic hPTH
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle followed by salmon calcitonin at an average dose of 79 units per day for a 56 day depressor period (Group 2)
Trial: 31711671
Drug: Digoxin administered
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin administered intraamniotically or intrafetally prior to second-trimester surgical abortion
Trial: 29863842
Drug: Onion-ring-like g-C3N4
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion-ring-like g-C3N4
Trial: 29863842
Drug: Bulk g-C3N4
RxNorm normalized name: psyllium
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulk g-C3N4
Trial: 23534333
Drug: RPE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPE treatment (n = 12)
Trial: 17437965
Drug: Cinitapride (CTP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinitapride (CTP; 1 mg t.i.d.) + ketoconazole (KET; 200 mg b.i.d.)
Trial: 17437965
Drug: Cinitapride (CTP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinitapride (CTP; 1 mg t.i.d.) + placebo (PL)
Trial: 17437965
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) + ketoconazole (KET; 200 mg b.i.d.)
Trial: 15362028
Drug: Mesalamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (3 g/day)
Trial: 25919835
Drug: Increase to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase to 30 mg/d of mirtazapine (increase(30) group)
Trial: 25919835
Drug: Maintain at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain at 15 mg/d of mirtazapine (stay(15) group)
Trial: 25919835
Drug: Increase to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase to 45 mg/d of mirtazapine (increase(45) group)
Trial: 25919835
Drug: Maintain at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain at 30 mg/d of mirtazapine (stay(30) group)
Trial: 22961272
Drug: Local injections
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injections of rhGH
Trial: 19773751
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by adjuvant chemotherapy
Trial: 17706059
Drug: Reduced osmolarity
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced osmolarity oral rehydration salts (ROORS)
Trial: 17706059
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts II (ORS II)
Trial: 15045139
Drug: IGIV-C (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C (1 g/kg/day for 2 days)
Trial: 15045139
Drug: IGIV-S/D (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-S/D (1 g/kg/day for 2 days)
Trial: 7493311
Drug: rIFN-alpha 3
RxNorm normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-alpha 3 MU thrice weekly (group A)
Trial: 7493311
Drug: rIFN-alpha 6
RxNorm normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-alpha 6 MU thrice weekly (group B)
Trial: 7493311
Drug: L-IFN 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-IFN 3 MU thrice weekly (group C)
Trial: 19756431
Drug: Peri-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peri-operative chemotherapy
Trial: 2148877
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no peri-operative chemotherapy)
Trial: 28961845
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg apatorsen
Trial: 28961845
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg apatorsen
Trial: 28961845
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg apatorsen (poor prognostic features)
Trial: 28961845
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg apatorsen (lower sHsp27 levels)
Trial: 28961845
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg apatorsen (lower sHsp27 levels)
Trial: 25742559
Drug: Acoustic wave
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic wave therapy (AWT)
Trial: 24444704
Drug: Standard conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conservative treatment (control)
Trial: 19829175
Drug: Lifestyle changes,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle changes, pharmacotherapy, and psychologic interventions
Trial: 11323363
Drug: Small Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small Ketamine (0.25 mg/kg)
Trial: 11323363
Drug: Large Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large Ketamine (1.0 mg/kg)
Trial: 9217714
Drug: Picotamide, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide, 600 mg twice daily
Trial: 3118579
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus glibenclamide
Trial: 2256787
Drug: Cefotaxime continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime continued treatment
Trial: 2256787
Drug: Ampicillin replacement
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin replacement treatment
Trial: 2256787
Drug: Phenobarbitone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone administration
Trial: 2256787
Drug: IV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV treatment cessation by the 10th day
Trial: 2256787
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with IIIrd generation cephalosporin
Trial: 2256787
Drug: Substitution by
RxNorm normalized name: hydroxypropyl corn starch (5% substitution by weight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution by ampicillin or amoxicillin
Trial: 1137256
Drug: Computer-assisted digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer-assisted digoxin therapy
Trial: 1137256
Drug: Physician-regulated digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician-regulated digoxin therapy
Trial: 27531181
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly 400 mg
Trial: 24925984
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole (10-30 mg/day)
Trial: 24925984
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly 50 mg
Trial: 22552758
Drug: Saffron (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (15 mg twice per day)
Trial: 15523183
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (RH)
Trial: 12490271
Drug: Angiopeptin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiopeptin 1.5 mg
Trial: 9620513
Drug: Ketamine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.4 mg/mL
Trial: 7542134
Drug: Finasteride (Proscar)
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride (Proscar) therapy for BPH
Trial: 19736899
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal sufentanil (5 microg) plus intrathecal morphine (150 microg)
Trial: 19736899
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal sufentanil (5 microg) plus single administration of 10 mg subcutaneous morphine
Trial: 17163810
Drug: Sitaxsentan with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan with concomitant warfarin
Trial: 52854
Drug: Oxprenolol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (60 mg per day) and Quinidine (0.60 g per day)
Trial: 52854
Drug: Quinidine (0.80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (0.80 g per day)
Trial: 30676622
Drug: Avelumab, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study
Trial: 26729394
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care and early electrical stimulation (ES) to the wrist flexors and extensors for 30 min twice a day, 5 days a week for 3 months
Trial: 22151064
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg · kg(‐1) GHB
Trial: 22151064
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg · kg(‐1) GHB
Trial: 22151064
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg · kg(‐1) GHB
Trial: 20619853
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (10 or 20 mg/day depending on age) for 10 days
Trial: 15726891
Drug: High-AGE (AGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-AGE (AGE 2.4 ml/day)
Trial: 15726891
Drug: Low-AGE (AGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-AGE (AGE 0.16 ml/day)
Trial: 31174215
Drug: Fe (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe (60 mg)
Trial: 27798075
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of mephedrone administered orally
Trial: 16922941
Drug: Pulsed Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Dye Laser (PDL) therapy following 30% Salicylic Acid (SA) application twice a day for 5 days
Trial: 16922941
Drug: Pulsed Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Dye Laser (PDL) therapy alone
Trial: 12712081
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment for three cycles followed by placebo for one cycle
Trial: 12712081
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for three cycles followed by placebo for one cycle
Trial: 11085959
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies to cardiolipin
Trial: 8500859
Drug: Captopril monotherapy
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril monotherapy or combined with hydrochlorothiazide
Trial: 8500859
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (metoprolol, hydrochlorothiazide, or both)
Trial: 8500859
Drug: Captopril or
RxNorm normalized name: captopril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril or conventional therapy
Trial: 29396092
Drug: Romiplostim (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (750 μg subcutaneously once per week for 58 weeks)
Trial: 11920549
Drug: Individualized uncertainty
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized uncertainty management intervention delivered by telephone (weekly phone calls for 8 weeks)
Trial: 2113376
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course (SC) of systemic antibiotics
Trial: 2113376
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course (LC) of systemic antibiotics
Trial: 391657
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg on entering the study followed by 400 mg six hourly)
Trial: 31614295
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training for 8 weeks, 7 days per week, twice daily
Trial: 19398166
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine replacement therapy
Trial: 16926171
Drug: Combination program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination program
Trial: 14960294
Drug: Estradiol (.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (.1 mg/day)
Trial: 11502805
Drug: Dexamethasone and
RxNorm normalized name: dexamethasone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone and prednisone treatment
Trial: 7953934
Drug: Comprehensive oral
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive oral health care programme
Trial: 2885080
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin and bleomycin) followed by standard therapy (surgery and postoperative radiotherapy)
Trial: 2885080
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy and standard therapy followed by maintenance chemotherapy (six cycles of monthly cisplatin)
Trial: 10812285
Drug: THC (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (15 mg)
Trial: 27514628
Drug: Routine Medical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Medical Therapy (RMT)
Trial: 25394549
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage (15 minutes, 2 times daily for 5 days)
Trial: 11061773
Drug: Epinephrine inhalation
RxNorm normalized name: EPINEPHrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine inhalation
Trial: 6135439
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg (i.v.) doxazosin
Trial: 6135439
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg (oral) doxazosin
Trial: 31337171
Drug: AAJ injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of 20 mg of triamcinolone, plus oral placebo tablets (2 tablets every 8 hours for one week)
Trial: 31337171
Drug: Systemic steroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroids, oral prednisolone tablets (5 mg, 2 tablets every 8 hours for one week), plus AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of normal saline solution
Trial: 29386173
Drug: Web-based tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based tailored cognitive behavioral therapy (CancerCope)
Trial: 27028912
Drug: Oral 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17β‐estradiol (1 mg per day, plus progesterone [45 mg] vaginal gel administered sequentially for women with a uterus)
Trial: 27028912
Drug: Placebo (plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (plus sequential placebo vaginal gel for women with a uterus)
Trial: 27028912
Drug: Oral 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17β‐estradiol and Placebo
Trial: 22824593
Drug: Grid laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grid laser treatment alone
Trial: 22824593
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravitreal injection of ranibizumab (0.5 mg / 0.05 ml) followed by grid laser treatment on 7th day
Trial: 22824593
Drug: Three loading
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three loading doses of intravitreal ranibizumab at monthly intervals + standard laser treatment 7 days after the 1st injection
Trial: 17229788
Drug: Consistent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistent use of a supervised safer injection facility (SIF)
Trial: 17229788
Drug: Inconsistent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inconsistent use of a supervised safer injection facility (SIF)
Trial: 9843009
Drug: 0.05% retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% retinaldehyde cream
Trial: 7978141
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 solution
Trial: 7978141
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 with metoclopramide 0.5 mg.ml‐1 solution
Trial: 2609898
Drug: Dithranol-Biogram formulation
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol-Biogram formulation (1% dithranol applied for 20 min after UV-B treatment)
Trial: 2609898
Drug: Conventional ex-tempore
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ex-tempore formulation (1% dithranol applied for 20 min after UV-B treatment)
Trial: 30477834
Drug: Lipoic Acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic Acid (LA) 1200 mg daily for 2 years
Trial: 26132079
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E)
Trial: 21910067
Drug: Xiongshao Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiongshao Capsule (XS)
Trial: 12715913
Drug: Tongue and
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue and oral mucosa cleaning (oral care) after lunch every day or every other day for two consecutive weeks
Trial: 11061760
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment (Curosurf, Survanta, Alveofact, Exosurf)
Trial: 20089269
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ciprofloxacin twice a day for 4 weeks
Trial: 18448709
Drug: Aggressive chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive chemotherapy for a 65-year-old patient
Trial: 18448709
Drug: Aggressive chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive chemotherapy for a 25-year-old patient (physician role)
Trial: 18448709
Drug: Aggressive chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive chemotherapy for a 25-year-old patient (abstract other role)
Trial: 18448709
Drug: Aggressive chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive chemotherapy for a 25-year-old patient (self role)
Trial: 16125527
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone plus testosterone (GH plus T) administration
Trial: 16125527
Drug: Sex steroid
RxNorm normalized name: Sex steroid binding globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex steroid administration (hormone replacement therapy in women, testosterone enanthate in men)
Trial: 11870507
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment with radioimmunotherapy in glioblastoma patients
Trial: 11870507
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment with radioimmunotherapy in grade III glioma patients